SOD1 and metabolic syndrome: Both Ang-(1–7) and A-1317 oral treatment in MetS rats, besides maintaining similar caloric intake, improved metabolism by reducing adiposity index, fasting blood glucose, OGTT, HOMA-IR, triglycerides, lipid peroxidation, AT1R, iNOS liver mRNA gene expression and carbonylated protein and MAP and increased eNOS and ECA2 liver mRNA gene expression and SOD activity.